Mankind Pharma to Acquire 70% Stake in ACTx for CAR-T Therapies

Mankind Pharma Limited announced its board has approved the acquisition of a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgian biotechnology company specializing in next-generation CAR-T therapies for cancer. This strategic move, part of Mankind Pharma's long-term vision for a global innovation-led pharmaceutical business, will be executed through its wholly-owned subsidiary, Mankind Pharma (Netherlands) B.V. The company will invest up to EUR 45 million in Mankind Netherlands, bringing the total investment limit to EUR 50 million, with EUR 48 million earmarked for the ACTx acquisition. ACTx's lead programs target non-Hodgkin lymphoma and small cell lung cancer. The acquisition is a cash consideration and is expected to be completed as per the definitive agreement.